Ahmed Salaheldin Zaki Moustafa

Dr. Ahmed Salaheldin Zaki Moustafa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RMRachael Morris
Rachael Morris
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
WKWondwosen Kassahun-Yimer
Wondwosen Kassahun-Yimer
SNSarah Novotny
Sarah Novotny
BBBrittney Billsby
Brittney Billsby
Kedra WallaceKedra Wallace
Kedra Wallace
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection has been associated with greater morbidity and increased mortality in certain populations, such as those with chronic medical conditions, the elderly, and pregnant women. Our goal was to determine if COVID-19 infection during pregnancy increased the risk of preeclampsia in a population of women with increased risk factors for preeclampsia. We present a prospective observational matched case–control study of 100 deliveries with confirmed SARS-CoV2. Specifically, we investigated the maternal and neonatal outcomes in a high-risk population of pregnant women. Among women with COVID-19, the severity of symptoms was associated with the incidence of preeclampsia, but not with pre-existing diabetes or hypertension. Women with more severe symptoms were more likely to delivery pre-term with smaller babies. After adjusting for diabetes, hypertensive women with COVID-19 had an increased risk of preeclampsia aOR4.3 [1.5,12.4] compared to non-hypertensive women with COVID-19. After adjusting for hypertension, women with diabetes and COVID-19 had an increased risk of preeclampsia aOR3.9 [1.2,12.5]. This relationship was not seen among women without COVID-19. For women who had pre-existing diabetes or hypertension, the risk of developing preeclampsia was only increased if they were also diagnosed with COVID-19, suggesting that in our population of women the risk of preeclampsia is not associated with pre-existing diabetes or hypertension.

11 April 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
ISIrene A. Stafford
Irene A. Stafford
MTMark A. Turrentine
Mark A. Turrentine
TOTiffany Ostovar-Kermani
Tiffany Ostovar-Kermani
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
ABAlexandra Berra
Alexandra Berra
HSHaleh Sangi-Haghpeykar
Haleh Sangi-Haghpeykar
Mortality figures and national health surveillance data have demonstrated that Hispanics have a 24% lower risk of all-cause mortality compared to their non-Hispanic counterparts despite increased r...

3 August 2026 in Pregnancy
Verified
Journal Article
Open access
PDF file
ZDZakaria Doughan
Zakaria Doughan
YBYossi Bart
Yossi Bart
JHJoe Haydamous
Joe Haydamous
LDLaura Diab
Laura Diab
Sara GiulianoSara Giuliano
Sara Giuliano
BSBaha M. Sibai
Baha M. Sibai
Background: Expectant management of early‐onset preeclampsia with severe features (<34 weeks’ gestation) requires close maternal surveillance. Although serial testing is routinely performed, recommendations regarding testing frequency vary across professional societies and the clinical utility and financial impact of frequent testing during expectant management remain uncertain. Objective: To describe the role of serial blood tests in guiding delivery decision‐making in preeclampsia with severe features, and to assess the health costs of these serial blood tests. Study Design: A retrospective cohort study of singleton pregnancies diagnosed with preeclampsia with severe features between 23 and 33 weeks at a level IV academic maternity center. Patients with contraindications to expectant management were excluded. Delivery indications were categorized by the contribution of blood test abnormalities: no abnormal blood tests contributing to delivery; blood test abnormalities detected once the decision for delivery was made, but not indication for delivery; and blood test abnormalities as the indication for delivery. Primary outcome was delivery prompted by abnormal blood test findings. Secondary outcomes included charges associated with serial testing. Data analysis included percent with 95% confidence intervals (CIs) or median with interquartile ranges (IQRs). Results: A total of 370 patients met inclusion criteria. Only five (1.4%; 95% CI, 0.4–3.1) had abnormal blood test values (transaminitis and/or thrombocytopenia) prompting delivery decisions, all appearing within 4 days of admission. Abnormal blood testing was not an indication for delivery for most patients ( N = 325; 87.8%; 95% CI, 84.1–91.0). For 40 patients (10.8%; 95% CI, 7.8–14.4), blood test abnormalities were detected after decision for delivery was made. The median number of blood tests per patient was 10 (IQR 6–14), and blood testing charge per patient was $5030 (IQR 3018–7042). The total charge for blood testing was $2.176 million over the study period. Conclusion: Among 370 patients with early‐onset preeclampsia with severe features managed expectantly, only 1% of the cohort had blood test abnormalities as the sole indication for delivery. All other patients were delivered either because of maternal‐fetal indications or developed blood test abnormalities occurring in association with other indications for delivery. Finally, serial blood testing in this setting resulted in total charges of $2.176 million over 9 years. Based on this large cohort, there is a need to reconsider the frequency of blood testing in the absence of new‐onset symptoms or worsening severe features.

18 September 2026 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
YBYossi Bart
Yossi Bart
ZDZakaria Doughan
Zakaria Doughan
LDLaura Diab
Laura Diab
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
BSBaha M. Sibai
Baha M. Sibai

21 November 2024 in Women
Verified
Journal Article
Open access
PDF file
GOGail Ohaegbulam
Gail Ohaegbulam
Kedra WallaceKedra Wallace
Kedra Wallace
WKWondwosen Kassahun-Yimer
Wondwosen Kassahun-Yimer
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
RMRachael Morris
Rachael Morris
The initial presentation of COVID-19 to the world left many in the medical community perplexed about its true nature and potential impact on individuals. Many investigations into the pathology of the virus resulted from this; however, studies were limited in the obstetric community, especially in high-risk communities. Each pandemic wave (Alpha, Delta, Omicron) had different transmission rates and inflicted different COVID-19 severity levels among those infected. This study aimed to determine if the effects of COVID-19 on maternal and infant outcomes varied by pandemic waves. This is an observational cohort study utilizing women enrolled in a COVID-19 pregnancy study. A review of 374 electronic medical records of women who received care at the University of Mississippi Medical Center after testing positive for SARS-CoV2 was conducted. During the Alpha pandemic wave, women contracted COVID-19 significantly earlier in pregnancy; however, higher rates of COVID-19 infection occurred during the Omicron pandemic wave. During the Delta pandemic wave, more women were morbidly obese and were likely to deliver significantly earlier, and, when compared to infants born during the Omicron pandemic wave, the infants born during the Delta wave weighed significantly less. The effects of COVID-19 on high-risk pregnant patients may deviate from previous reports, indicating a need for further investigation of the biological and social factors that may lead to these differences. Studies into the effects of COVID-19 in pregnancy remain limited and this study provides valuable insight into how varying COVID-19 strains affected a high-risk obstetric community.

4 July 2025
Verified
Preprint
Open access
RHRebecca Horgan
Rebecca Horgan
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
MMMackenzi Mchugh
Mackenzi Mchugh
TKTetsuya Kawakita
Tetsuya Kawakita
BSBaha Sibai
Baha Sibai
GSGeorge Saade
George Saade